ALLR — Allarity Therapeutics Share News
0.000.00%
Last trade - 00:00- $13.77m
- $19.07m
- $0.32m
Brief: Allarity Therapeutics Announces Changes To Board Of Directors
Brief: Allarity Therapeutics Cash & Cash Receivable Balance Of $20.9 Million As Of Dec 31, Expected To Fund Operations, Including Clinical Activities Into 2027
Brief: Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission
Brief: Allarity Therapeutics Announces Board Authorization Of $5 Million Share Repurchase Program
Brief: Allarity Therapeutics To Pay $2.5 Million Civil Penalty
Brief: Allarity Therapeutics Reports Key Progress In Phase 2 Stenoparib Trial
Brief: Allarity Therapeutics To Be Granted European Patent For Drp Companion Diagnostic For Stenoparib
Brief: Allarity Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Allarity Therapeutics Appoints Alex Epshinsky As CFO
Brief: Allarity Therapeutics Says Received Notice Of Resignation From Joan Brown, Its CFO
Brief: Allarity Therapeutics Says Nasdaq Hearings Panel Approved Allarity's Plan To Maintain Its Listing
Brief: Allarity Therapeutics Inc Says Raises Size Of Common Stock Offering To $50 Million From $30 Million - SEC Filing
Brief: Allarity Therapeutics Says Filed Sixth Certificate Of Amendment To Decrease Number Of Authorized Shares
Brief: Allarity Therapeutics Postpones Annual Stockholders Meeting
Brief: Allarity Encourages Shareholders To Vote For The Reverse Stock Split And Decrease In Authorized Shares
Brief: Allarity Therapeutics - On July 19, Co Received A "Wells Notice" From Staff Of U.S. SEC Relating To Co's Previously Disclosed SEC Investigation
Brief: Allarity Granted Hearing Before Nasdaq Panel To Present Plan Of Regaining Compliance
Brief: Allarity Therapeutics Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement
Brief: Allarity Therapeutics' Stenoparib Sees Early Conclusion Of Phase 2 Trial In Advanced Ovarian Cancer